Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
Br J Pharmacol. 2019 Jan;176(2):147-154. doi: 10.1111/bph.14527. Epub 2018 Dec 3.
Nitric oxide (NO) plays important roles in gastrointestinal mucosal defence, as well as in the pathogenesis of several gastrointestinal diseases (e.g. irritable bowel syndrome and inflammatory bowel disease). The potent cytoprotective effects of NO have been demonstrated in a range of animal models. However, in some disease states, inhibition of NO synthesis is beneficial. Several attempts have been made to develop drugs for ulcerative and/or inflammatory disorders of the gastrointestinal tract, with varying degrees of success. Covalently linking a NO-releasing group to non-steroidal anti-inflammatory drugs or to drugs used in the treatment of inflammatory bowel disease and irritable bowel syndrome has shown some benefit, although no drug of this type has yet been fully developed. LINKED ARTICLES: This article is part of a themed section on Nitric Oxide 20 Years from the 1998 Nobel Prize. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.2/issuetoc.
一氧化氮(NO)在胃肠道黏膜防御以及多种胃肠道疾病(如肠易激综合征和炎症性肠病)的发病机制中发挥着重要作用。在一系列动物模型中,NO 的强大细胞保护作用已经得到了证实。然而,在某些疾病状态下,抑制 NO 合成是有益的。人们已经尝试开发用于治疗胃肠道溃疡性和/或炎症性疾病的药物,但取得的成功程度不一。将 NO 释放基团与非甾体抗炎药或用于治疗炎症性肠病和肠易激综合征的药物共价连接已显示出一定的益处,尽管尚未完全开发出此类药物。
本文是从 1998 年诺贝尔奖回顾一氧化氮 20 年专题的一部分。要查看本专题中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.2/issuetoc.